Empowered Funds’s AbbVie ABBV Stock Holding History

Empowered Funds’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,137	Closed	-$3.09M	–	513
2022 Q4	$3.09M	Buy	+19,137	New	+$2.93M	0.2%	146

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Empowered Funds's ABBV Position: Q2 2026 in Review

Empowered Funds reduced its AbbVie (ABBV) stake by 11% in Q2 2026, selling an estimated $5.27M and leaving 202,359 shares worth $50.9M. The position accounts for 0.27% of the portfolio, ranked #66.

Empowered Funds first reported a position in ABBV in Q4 2017 and has held it in 23 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Empowered Funds held 202,359 shares of AbbVie worth $50.9M as of Q2 2026.
Empowered Funds sold 24,477 AbbVie shares in Q2 2026, an estimated $5.27M.
AbbVie made up 0.27% of Empowered Funds's portfolio in Q2 2026, its #66 holding.
Empowered Funds first reported a position in AbbVie in Q4 2017 and has held it in 23 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.